Sickle Cell Disease Treatment Market Revenue Expansion and Share Analysis 2034
Sickle Cell Disease Treatment Market Revenue Expansion and Share Analysis 2034
The Sickle cell disease treatment market size in 2026 is an inherited disorder that causes the deformation of red blood cells. The condition can lead to the early destruction of blood cells and restrict normal blood flow by creating blockages. Sickle cell disease includes conditions such as hemoglobin sickle cell disease, hemoglobin SS disease, and sickle cell anemia. Treatment approaches include blood transfusions, pharmacotherapy, and bone marrow transplantation. Growing awareness of the disease, increasing prevalence, and greater emphasis among market players on developing and introducing effective treatments are shaping the evolution of the global sickle cell disease treatment market.
According to Fortune Business Insights, the global sickle cell disease treatment market size was estimated at USD 3.94 billion in 2025 and is projected to reach USD 4.73 billion in 2026 and USD 20.47 billion by 2034, growing at a CAGR of 20.10% from 2026 to 2034. The United States dominated the market with a 63.35% share in 2025. The market is being influenced by increasing disease prevalence, the need to manage severe complications, advances in pharmacotherapy, and the development of innovative treatment approaches.
The treatment landscape for sickle cell disease has expanded beyond conventional management approaches. Blood transfusion, bone marrow transplantation, and pharmacotherapy form the major treatment modalities covered in the market. Pharmacotherapy includes hydroxyurea and branded products, while continued research and product development are supporting the emergence of additional treatment candidates.
Increasing attention toward novel treatment solutions is an important feature of the market. Fortune Business Insights highlights the growing focus of leading companies on new products designed to address the needs of patients with sickle cell disease. The introduction of Endari, followed by products such as Oxbryta, Adakveo, Zynteglo, and PYRUKYND, reflects the expanding product landscape.
Gene therapy has emerged as an important area of research within sickle cell disease treatment. Market participants have increasingly focused their research and development activities on approaches designed to address the genetic basis of hereditary diseases. The Fortune Business Insights report highlights research involving lentiviral gene transfer and CRISPR-Cas9 gene-edited therapy.
The development of pipeline candidates is contributing to the changing treatment environment. Research into genetic correction and gene-editing approaches is expected to support the introduction of additional treatment solutions during the forecast period. These developments are also increasing the focus on advanced therapies within the sickle cell disease treatment industry.
The increasing prevalence of sickle cell disease is creating demand for effective treatment procedures. Fortune Business Insights notes that millions of people globally are affected by the condition. Patients can experience severe complications, including vaso-occlusive crises, which can result in sudden and acute discomfort and increase the need for emergency medical care.
The need to reduce the severity and frequency of complications is encouraging the adoption of available therapies. Increasing emphasis by leading companies on treatments designed to address disease complications is also contributing to market expansion. Product approvals and expanded indications have further supported the adoption of pharmacotherapy for eligible patient groups.
The market is driven by the increasing prevalence of sickle cell disease, growing awareness, and the development of new treatment solutions. The increasing focus of pharmaceutical companies on introducing effective drugs is supporting market expansion. Government support for research and the use of designations such as orphan drug, fast track, and priority review are also contributing to the development and introduction of new therapies.
At the same time, limited treatment availability in emerging countries remains a market restraint. Fortune Business Insights highlights the limited availability and affordability of hydroxyurea in parts of Sub-Saharan Africa despite its inclusion in the WHO Model List of Essential Medicines for Children. Blood transfusion treatment also depends on donor availability and appropriate screening. Insufficient public and private funding for healthcare infrastructure and limited disease awareness in emerging economies can further restrict market development.
Bristol-Myers Squibb Company (U.S.)
Addmedica (France)
Novartis AG (Switzerland)
Global Blood Therapeutics, Inc. (Pfizer Inc.) (U.S.)
Emmaus Medical, Inc. (U.S.)
bluebird bio Inc. (U.S.)
Agios Pharmaceuticals, Inc. (U.S.)
By Treatment Modality [Bone Marrow Transplant, Blood Transfusion, Pharmacotherapy {Hydroxyurea, and Branded Products (Endari, Adakveo, Oxbryta, Zynteglo, PYRUKYND (Mitapivat), CTX001, Inclacumab, MGTA-145, Vamifeport (VIT-2763), ALXN1820, FT-4202, and GBT021601)}]
By End-user [Hospitals, Specialty Clinics, and Others]
Explore the full research report with detailed insights and TOC: https://www.fortunebusinessinsights.com/industry-reports/sickle-cell-disease-treatment-market-101009
U.S.: The United States dominated the global market with a valuation of USD 2.49 billion in 2025 and USD 3.00 billion in 2026. The country accounted for a 63.35% market share in 2025. Better access to treatment, potential pipeline candidates, government support, and collaborations focused on improving disease treatment are supporting market development.
Europe: Europe accounted for a significant market share and is projected to experience considerable growth. Favorable reimbursement policies, increasing disease prevalence, and the expansion of product offerings by market participants are supporting regional development.
Middle East & Africa: The market is expected to expand at a significant CAGR in the projected years. Growth is supported by the high incidence of sickle cell disease in the Middle East & Africa, Mediterranean regions, and South America, along with rising disposable income, increasing awareness, and a strong pipeline of branded drugs.
Asia Pacific: Growth is driven by rising disease awareness, expanding healthcare access, and increasing government initiatives for sickle cell disease management.
Japan: Market development is supported by advancements in rare disease treatment, increasing healthcare investment, and expanding access to innovative therapies.
The future of the sickle cell disease treatment market is closely associated with the development of innovative therapies, expanding pharmacotherapy options, increasing awareness, and growing treatment demand. Fortune Business Insights identifies the wave of innovation in SCD therapeutics, increasing disease prevalence, and approvals of advanced pharmacotherapy drugs as key factors supporting market growth.Continued research into gene therapy and gene-editing approaches, combined with the introduction of novel branded treatments, is expected to reshape the treatment landscape. Government initiatives and regulatory support for advanced therapies may further encourage research and product development. Expansion of treatment access and growing awareness in emerging markets are also important areas for future market development.
What’s Driving Japan’s Market? Discover the Latest -Sickle Cell Disease Treatment Market- Insights